Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pulmonary Arterial Hypertension

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    267 result(s) found for: Pulmonary Arterial Hypertension. Displaying page 1 of 14.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2009-014534-15 Sponsor Protocol Number: NACIPP Start Date*: 2009-10-01
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: EFFECT OF ACUTE ADMINISTRATION OF N-ACETYLCYSTEINE ON BLOOD PRESSURE OF PULMONARY ARTERIAL IN PRIMARY PULMONARY HYPERTENSION.
    Medical condition: PRIMARY PULMONARY HYPERTENSION
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036727 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-003847-37 Sponsor Protocol Number: REM 04 15 Start Date*: 2004-12-21
    Sponsor Name:BIOPROJET
    Full Title: An Open label uncontrolled study of the safety and efficacy of chronic intravenous Remodulin in patients with pulmonary Arterial Hypertension
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    6.1 10037400 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002835-17 Sponsor Protocol Number: 250774 Start Date*: 2016-01-18
    Sponsor Name:Justus Liebig Universität Gießen
    Full Title: Investigation of the influence of PAH-specific medication on right ventricular function in patients with pulmonary arterial hypertension (PAH) under basal conditions
    Medical condition: Pulmonary arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037403 Pulmonary hypertension NOS LLT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10077729 Pulmonary arterial hypertension WHO functional class III LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10077740 Pulmonary arterial hypertension WHO functional class II LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2016-000347-14 Sponsor Protocol Number: PROCLAIM Start Date*: 2016-06-16
    Sponsor Name:IDIBAPS
    Full Title: Cell proliferation in pulmonary hypertension: mollecular imaging detection by FDG PET. Comparative study between patients and healthy subjects
    Medical condition: Pulmonary artery hypertension and thromboembolic chronic pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10037405 Pulmonary hypertension primary LLT
    19.0 100000004855 10068739 Chronic thromboembolic pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000709-38 Sponsor Protocol Number: BBR Start Date*: 2015-10-20
    Sponsor Name:Medical University of Graz
    Full Title: Acute Effects of Benzbromaron on the pulmonary circulation
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003975-38 Sponsor Protocol Number: TERPAH-001 Start Date*: 2007-11-22
    Sponsor Name:Ergonex Pharma GmbH
    Full Title: Proof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective P...
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036727 Primary pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) NL (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004224-37 Sponsor Protocol Number: EREMIT Start Date*: Information not available in EudraCT
    Sponsor Name:Universität Leipzig
    Full Title: Everolimus in der Therapie von Patienten mit pulmonaler Hypertonie
    Medical condition: - steady or progressive pulmonary hypertension accompanied by at least two of the following parameters associated with a poor prognosis: - Cardiac index ≤ 2,1 l/min/m2 - 6 MWD ≤ 380 m - systolic RR...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037400 Pulmonary hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017155-10 Sponsor Protocol Number: 10-aifa-2005-01 Start Date*: 2006-11-07
    Sponsor Name:CASA DI CURA PRIVATA S.RAFFAELE - PISANA
    Full Title: Evaluation of tolerability and efficacy of the combination Sildenafil/Bosentan in patients with severe pulmonary hypertension.
    Medical condition: severe pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001643-21 Sponsor Protocol Number: 2007OE002B Start Date*: 2008-06-26
    Sponsor Name:Royal Brompton and Harefield NHS Trust
    Full Title: Use of endothelin-1 antagonists in patients with Established Pulmonary Hypertension and Fibrotic Lung Disease. – A randomised, placebo-controlled, double-blinded study.
    Medical condition: Pulmonary hypertension in patients with interstitial lung disease.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-006453-12 Sponsor Protocol Number: NS-304/-03 Start Date*: 2008-07-21
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: A multi-centre, multinational, open- label study to evaluate the long-term safety, tolerability and efficacy of selexipag / ACT-293987 (NS-304) in the treatment of pulmonary arterial hypertension i...
    Medical condition: Pulmonary arterial hypertension (PAH) (idiopathic PAH, familial PAH, and PAH associated with collagen disease, corrected congenital vitium or anorexigen use
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) FR (Completed) BE (Completed) GB (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001675-37 Sponsor Protocol Number: Lis-Safe Start Date*: 2012-07-24
    Sponsor Name:Sinoxa Pharma GmbH
    Full Title: A Prospective, Open-label, Exploratory Study to Investigate the Safety, Efficacy, and Haemodynamics of Lisuride Subcutaneous Infusion as Add-on to Conventional Treatment in Patients with Pulmonary ...
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004855 10036727 Primary pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-003694-27 Sponsor Protocol Number: AC-055-303 Start Date*: 2011-11-17
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: SERAPHIN-OL: Study with an ERA in Pulmonary arterial Hypertension to Improve cliNical outcome (Open Label) Long-term single-arm open-label extension study of the SERAPHIN study, to assess the safe...
    Medical condition: symptomatic pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) FR (Completed) FI (Prematurely Ended) SE (Completed) AT (Completed) BE (Completed) DK (Completed) SK (Completed) PT (Prematurely Ended) IT (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2011-001893-24 Sponsor Protocol Number: Bay63-2521/14986 Start Date*: 2011-10-13
    Sponsor Name:Bayer HealthCare AG
    Full Title: Relative bioavailability and food effect study of two oral liquid formulations in comparison to a 1mg tablet of riociguat to characterize its pharmacokinetic properties in healthy male and female a...
    Medical condition: Children with PH due to • Pulmonary arterial hypertension (PAH) • persistent pulmonary hypertension of the newborn (PPHN)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037405 Pulmonary hypertension primary LLT
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10036727 Primary pulmonary hypertension LLT
    14.0 10010331 - Congenital, familial and genetic disorders 10053592 Newborn persistent pulmonary hypertension LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004806-32 Sponsor Protocol Number: RAMSES Start Date*: 2019-03-02
    Sponsor Name:ITALIAN PULMONARY HYPERTENSION NETWORK, IPHNET
    Full Title: Right ventriculAr reverse reModeling and hemodynamic improvement after add-on combination therapy (ambriSentan/PDE-5i) in PAH patientS (RAMSES)
    Medical condition: patients with pulmonary arterial hypertention
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-010703-80 Sponsor Protocol Number: AC-063A301 Start Date*: 2009-06-11
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients with Symptomatic Pulmonary ...
    Medical condition: Indication: Symptomatic Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-001645-17 Sponsor Protocol Number: 2007OE003B Start Date*: 2007-12-04
    Sponsor Name:Royal Brompton and Harefield NHS Trust
    Full Title: Prevention of Established Pulmonary Hypertension in High Risk patients with Fibrotic Lung Disease – a double-blinded, randomised, placebo controlled trial with endothelin-1 receptor antagonist the...
    Medical condition: Pulmonary hypertension in patients with interstitial lung disease. Specifically this trial looks at patients who have mild pulmonary hypertension, or are in an at-risk group to developing pulmonar...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-018436-41 Sponsor Protocol Number: Bay 63-2521/14554 Start Date*: 2010-05-11
    Sponsor Name:Bayer HealthCare AG
    Full Title: Acute hemoDynamic effects of RIociguat (BAY 63-2521) in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE 1): A randomized, double-blind, placebo-controlled, sin...
    Medical condition: Pulmonary hypertension associated with diastolic heart failure
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037405 Pulmonary hypertension primary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) CZ (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003621-24 Sponsor Protocol Number: MG-101-01 Start Date*: 2008-05-29
    Sponsor Name:MondoGEN AG
    Full Title: Double-blind, randomized, placebo-controlled, dose-finding, parallel-group study to assess the hemodynamic effects, clinical efficacy, tolerability and safety of Aviptadil (Vasoactive Intestinal Pe...
    Medical condition: Pulmonary arterial hypertension (PAH) due to idiopathic pulmonary arterial hypertension (IPAH), familial PAH or PAH associated with connective tissue diseases (CTD) (e.g. systemic sclerosis, system...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    9.1 10065151 Idiopathic pulmonary arterial hypertension LLT
    9.1 10065152 Familial pulmonary arterial hypertension LLT
    9.1 10065150 Associated with pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) NL (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-003328-39 Sponsor Protocol Number: NS-304/-02 Start Date*: 2008-04-25
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: A multi-centre, multinational, open-label single-dose acute hemodynamic study followed by a multi-centre, multinational, randomized, double-blind, parallel-group, placebo controlled study to assess...
    Medical condition: pulmonary arterial hypertension (PAH) (idiopathic PAH, familial PAH, and PAH associated with collagen disease, corrected congenital vitium or anorexigen use)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065151 Idiopathic pulmonary arterial hypertension LLT
    9.1 10065152 Familial pulmonary arterial hypertension LLT
    9.1 10065150 Associated with pulmonary arterial hypertension LLT
    9.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) DE (Completed) HU (Completed) AT (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002783-12 Sponsor Protocol Number: BAYq6256/16483 Start Date*: 2014-01-07
    Sponsor Name:Bayer HealthCare AG
    Full Title: A multi-center, open-label, randomized cross-over study to compare the acute tolerability and pharmacokinetics of BAY Q 6256 (iloprost; Ventavis) inhalation using the I-Neb nebulizer and the FOX ne...
    Medical condition: Patients with Pulmonary arterial hypertension, WHO class III, who have been on therpay with Ventavis 10 for at least 4 weeks
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10036727 Primary pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:11:46 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA